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Diagnosis, management and outcome of Candida endocarditis
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Abstract
Limited data exist on Candida endocarditis (CE) outcome in the era of new antifungals. As early diagnosis of CE remains difficult, non-
culture-based tools need to be evaluated. Through the French prospective MYCENDO study (2005–2007), the overall characteristics
and risk factors for death from CE were analysed. The contribution of antigen detection (mannan/anti-mannan antibodies and (1,3)-b-D-
glucans) and molecular tools was evaluated. Among 30 CE cases, 19 were caused by non-albicans species. Sixteen patients (53%) had a
predisposing cardiac disease, which was a valvular prosthesis in ten (33%). Nine patients (30%) were intravenous drug users; none of
them had right-sided CE. Among the 21 patients who were not intravenous drug users, 18 (86%) had healthcare-associated CE. Initial
therapy consisted of a combination of antifungals in 12 of 30 patients (40%). Thirteen patients (43%) underwent valve replacement. The
median follow-up was 1 year after discharge from hospital (range, 5 months to 4 years) and hospital mortality was 37%. On univariate
analysis, patients aged ‡60 years had a higher mortality risk (OR 11, 95% CI 1.2–103.9; p 0.024), whereas intravenous drug use was
associated with a lower risk of death (OR 0.12, 95% CI 0.02–0.7; p 0.03). Among 18 patients screened for both serum mannan/anti-
mannan antibodies and (1,3)-b-D-glucans, all had a positive result with at least one of either test at CE diagnosis. Real-time PCR was
performed on blood (SeptiFast) in 12 of 18, and this confirmed the blood culture results. In conclusion, CE prognosis remains poor,
with a better outcome among younger patients and intravenous drug users. Detection of serum antigens and molecular tools may con-
tribute to earlier CE diagnosis.
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